Paolo Appendino

Dr. Paolo Appendino

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2025 in Dentistry Journal
Verified
Journal Article
Open access
PDF file
Andrea ScribanteAndrea Scribante
Andrea Scribante
PAPaolo Appendino
Paolo Appendino
Carolina MaioraniCarolina Maiorani
Carolina Maiorani
PFPaolo Fontanarosa
Paolo Fontanarosa
MPMaurizio Pascadopoli
Maurizio Pascadopoli
Andrea ButeraAndrea Butera
Andrea Butera
Objectives: The aim of this six-month randomized controlled study was to evaluate the efficacy of a non-surgical periodontal treatment combined with the use of an active gel compared to a non-surgical treatment alone in reducing inflammatory indices in periodontal patients with Down syndrome. Methods: A total of 40 patients were included in the study, 20 of which were assigned to the active group and 20 to the control group. The active group underwent non-surgical periodontal treatment supplemented by daily home application of an intensive soothing gel containing probiotics. The control group received non-surgical periodontal treatment combined with the application of a gel without active ingredients. The following clinical indices were assessed: Bleeding on Probing (BOP %), Plaque Control Record (PCR %), Mobility (Miller Index), and Modified Marginal Gingival Index (MGI). Measurements were taken at baseline (T0), one month after treatment initiation (T1), after three months (T2), and after six months (T3). The patient compliance was evaluated at each visit, and product satisfaction was assessed through a questionnaire using a Visual Analogue Scale (VAS). Results: By the end of the study, statistically significant improvements were observed in both the groups from T0 to T3 evaluation (p < 0.05). The BOP score was significantly lower in the Trial group at the T3 intergroup evaluation (p < 0.05). Conclusions: A soothing gel with postbiotic and natural compounds was a valuable adjunct to non-surgical periodontal treatment to improve periodontal health in patients with Down syndrome, reducing BOP after 6 months of treatment.

25 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
DKDORA KARIMI
DORA KARIMI
PAPaolo G. Arduino
Paolo G. Arduino
AGAlessio Gambino
Alessio Gambino
Francesco Maria ErovigniFrancesco Maria Erovigni
Francesco Maria Erovigni
ADAlessandro Dell’acqua
Alessandro Dell’acqua
Vittorio FuscoVittorio Fusco
Vittorio Fusco
Objectives: To assess the number of new cases of Medication-Related Osteonecrosis of the Jaw (MRONJ) among patients with osteoporosis and other non-malignant bone diseases in Northwestern Italy between 2007 and 2022. Methods: MRONJ cases were collected from referral centers in a population of 4.5 million. We analysed the number of new MRONJ cases per year, type of disease, administered drugs, duration of therapy (when available), and onset time of disease. Results: We analysed 198 cases (out of 1071 total MRONJ cases); diseases included osteoporosis (87%), rheumatoid arthritis (5%), their association (4%), Paget’s disease, and other various diseases (4%). Patients received bisphosphonates alone (74%), or denosumab alone (6%), or a sequence of different drugs (20%). The number of new cases increased over five years from 2 (2003–2007) to 51 (2008–2012), 65 (2013–2017), and 79 (2018–2022), and the percentage increased from 1% to 14%, 20%, and 29% of the total cases. Conclusions: The number of new MRONJ cases per year among patients with non-malignant diseases is rapidly increasing all around the world, though underestimation cannot be excluded. In this study, we describe epidemiological and clinical characteristics of patients, and the drug most frequently involved in MRONJ cases in our region over a long period, allowing a comprehensive view of the progression of the disease. Greater collaboration among specialists is needed for correct and early diagnosis to improve measures potentially reducing disease incidence and to limit quality of life deterioration in patients with osteoporosis and other non-malignant diseases.

9 December 2025 in Clinical Oral Investigations
Verified
Journal Article
Open access
PDF file
LGLuca Guaschino
Luca Guaschino
AVAlessandro Vanzanelli
Alessandro Vanzanelli
PBPiermarco Babando
Piermarco Babando
ARAndrea Ricotti
Andrea Ricotti
GRGuglielmo Amedeo Ramieri
Guglielmo Amedeo Ramieri
PAPaolo Appendino
Paolo Appendino
Objectives: To evaluate the efficacy of ozone therapy on pain reduction, trisma and number of analgesic tablets taken following surgical removal of impacted mandibular third molar. Methods: A split-mouth randomized clinical trial was conducted in 54 patients in need of bilateral impacted mandibular third molars (Pell-Gregory class II-B) extraction. Test sites were treated with adjunctive ozone therapy to the surgical extraction, while controls underwent surgical intervention only (time between surgeries: 3 weeks). Study primary outcome measure was the difference in perceived pain recorded using a Numerical Rating Scale (NRS) at 7 days after surgery. In addition, functional limitation in mouth opening (mm), number of analgesic tablets taken within one week after surgery as well as the patient’s perceived quality of life (Oral Health Impact Profile (OHIP-14) were evaluated. Results: Fifty patients (20 males and 30 females; median age: 21 years; all non-smokers) completed the study. Mean reported perceived pain decrease from 5.06 to 0.58 (test group) and from 5.62 to 1.08 (control group) between day 1 and 7. No statistically significant differences were detected between the two groups at any time points ( p > 0.05). At day 7, mean mouth opening value was 40.8 vs. 36.6 mm in test and control group respectively (mean difference: 4.24 mm; p < 0.001; 95% CI: 6.55–1.93). The same trend was detected for the of number of analgesic tablets taken (median: 4 vs. 7; p = 0.01). Finally, OHIP-14 values did not differ between groups ( p > 0.05). Conclusion: Ozone therapy had a beneficial clinical effect in terms of mouth opening and in the number of analgesic tablets intake at 7 days after surgical removal of impacted mandibular third molar, despite the lack of adjunctive benefit on patients perceived pain reduction. Clinical relevance: The clinical use of ozone therapy as adjunct to surgical removal of impacted mandibular third molar might be considered in light of the promising positive reported results in terms of mouth opening reduction and analgesic intake. Clinical trial registration number: NCT05949476

22 September 2026 in Journal of Oral Rehabilitation
Verified
Journal Article
Open access
PDF file
JFJavier Fernández‐Feijoo
Javier Fernández‐Feijoo
MBManuel Bratos‐Bobo
Manuel Bratos‐Bobo
MBManuel Bratos‐Morillo
Manuel Bratos‐Morillo
DFDenise Faulks
Denise Faulks
MBMarie‐Sophie Bogner
Marie‐Sophie Bogner
Marcio Diniz-FreitasMarcio Diniz-Freitas
Marcio Diniz-Freitas
Background: Adults with intellectual disabilities often experience tooth loss and face barriers to accessing implant‐supported rehabilitation. Objective: To evaluate implant‐supported prosthesis outcomes in adults with non‐syndromic intellectual disabilities and to identify variables associated with prosthetic success. Methods: A total of 247 implant‐supported prostheses placed in 137 patients from 7 dental centers in Spain, France, Italy, and South Korea were analysed. Patient characteristics, oral health, implant features, and prosthesis‐related variables were collected. Prosthetic outcomes were categorized as “undamaged and successful”, “damaged but successful”, “loss”, or “undamaged but unsuccessful”. Success was assessed using an adapted United States Public Health Service (USPHS) clinical rating system. Results: At a mean follow‐up of 68.1 months, 94.3% of prostheses were considered successful. Cumulative survival rates were 97% at 5 years, 88% at 10 years, and 85% at 15 years. The most common technical complications were screw loosening (10.4%) and chipping (10%). Fixed prostheses predominated (92.3%), with 65.3% crowns and 34.6% bridges. Screw retention was most common (84.2%), and 94.3% followed a conventional loading protocol. General anaesthesia was used in nearly half of the cases during the impression step, although most framework and delivery procedures were performed without sedation. Among the multinomial mixed‐effects models, implant design was significantly associated with the outcome category “damaged but successful”, whereas age at first implant surgery was significantly associated with the outcome category “loss” (OR = 0.93 per additional year; 95% CI: 0.87–0.99; p = 0.031). However, the model showed no overall discriminatory ability (AUC‐ROC = 0.500), and these associations should therefore be considered exploratory rather than clinically predictive. Random‐effects binomial models showed improved discrimination (AUC‐ROC = 0.754), although no statistically significant associations were identified. Conclusion: Implant‐supported prosthetic rehabilitation is a viable and successful long‐term treatment option for adults with non‐syndromic intellectual disabilities, achieving outcomes comparable to those in the general population.